Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.38 |
| ▸ | BCR | P11274 | 5/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473159 | 0.85 | BRAF (0.44) | BRAF | |
| SCHEMBL4482580 | 0.81 | KDM4E (0.34) | BRAFABL1GPBAR1 | |
| SCHEMBL4491870 | 0.77 | EGLN1 (0.35) | ABL1BCREGLN1 | |
| SCHEMBL4463288 | 0.77 | RXRA (0.37) | ABL1BCREGLN1HPGDSALKBH2 | |
| SCHEMBL4479194 | 0.77 | RXRA (0.37) | ABL1BCREGLN1HPGDSALKBH2 | |
| SCHEMBL4478485 | 0.76 | ABL1 (0.37) | BRAFABL1BCREGLN1 | |
| SCHEMBL4486668 | 0.75 | XDH (0.40) | EGLN1 | |
| SCHEMBL4466806 | 0.73 | BRAF (0.41) | BRAF | |
| SCHEMBL4484455 | 0.72 | ABL1 (0.42) | BRAFABL1BCREGLN1 | |
| SCHEMBL4478699 | 0.72 | EGLN1 (0.44) | BRAFABL1BCREGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | claimed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | claimed |
| US-7485657-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1756065-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005115991-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256113-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL2 | BRAF 4079/4885ABL1 1997/4885BCR 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.